Anti-S. typhi Vi IgG levels in children with and without typhoid vaccinations

Sriandayani Sriandayani; Tonny H. Rampengan; Hesti Lestari; Novie Rampengan

doi:10.14238/pi54.5.2014.284-8

Sriandayani Sriandayani Department of Child Health, Sam Ratulangi University Medical School/Prof. Dr. R. D. Kandou Hospital, Manado
Tonny H. Rampengan Department of Child Health, Sam Ratulangi University Medical School/Prof. Dr. R. D. Kandou Hospital, Manado
Hesti Lestari Department of Child Health, Sam Ratulangi University Medical School/Prof. Dr. R. D. Kandou Hospital, Manado
Novie Rampengan Department of Child Health, Sam Ratulangi University Medical School/Prof. Dr. R. D. Kandou Hospital, Manado

DOI: https://doi.org/10.14238/pi54.5.2014.284-8

Keywords: anti-S. typhi Vi IgG, Vi polysaccharide typhoid vaccin e, , typhoid fever, children

Abstract

Background Typhoid fever is endemic to Indonesia, with an annual incidence of 13/10,000 people. Vaccination has been shown to be an effective method to prevent typhoid fever. Of several vaccine types, the polysaccharide Vi vaccine is the most commonly used typhoid vaccine in developing countries. Results of previous studies remain inconclusive on the necessity of revaccination every 3 years.

Objective To compare the mean serum anrioody titers of anti-S. typhi Vi IgG and the proportion of children with protective antibody levels between children with and without typhoid Vi vaccination.

Methods We conducted a cross-secrional study at Tuminring District, 11anado from June to September 2012. Data was analyzed using independent T-test and Fisher's test. Serum anti-S. typhi Vi IgG levels were measured by enzyme-linked immunosorbent assay (ELISA) method.

Results Seventy-six subjects were divided into two groups: 38 children who had received the typhoid Vi vaccination more than 3 years prior to this study and 38 children who never had typhoid vaccinations as a control group. No statistically significant difference in age and gender was found between the two groups. The mean serum anti-Vi IgG level was 0.55 ug/mL (SD 0.58; 95%CI 0.36 to 0.74) in the vaccinated group, significantly higher than that of the control group [0.31 ug/mL (SD 0.12); 950/Â£1 0.17 to 0.44; Pô€‚¥0.0381. The proportion of children with protective antiNi antioody level was higher in the vaccinated group (23.7%) than in the control group Â (10.5%), howevet; this difference was not statistically significant (P=0.128).

Conclusion The mean serum anti-S. typhi Vi IgG antibody level in children who had been vaccinated more than 3 years prior to the study is higher than in children who had never received typhoid vaccinations. Nevertheless, the mean antibody titers are generally non-protective in ooth groups. Also, the proportion of children with protective antibody levels is not significantly different between the two groups.

References

Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A, et al. Vaccines against typhoid fever. Vaccine. 2006;24:3804-11.

Bhutta ZA, Khan MI, Soofi SB, Ochiai Ri. New advances in typhoid fever vaccination strategies. Adv Exp Med Biol. 2011;697:17-38.

Maskey Ap, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg. 2008;102:91-5.

Punda-Polic V, Kraljevic KS, Bradaric N. War-associated cases of typhoid fever imported to Split-Dalmatia County (Croatia). Mil Med. 2007;172:1096-8.

Crump JA, Luby Sp, Mintz ED. T he global burden of typhoid fever. Bull World Health Organ. 2004;82:346-53.

Crump JA, Ram PK, Gupta SK, Miller 11A, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infection in low and medium human development index countries, 1984-2005. Epidemiol Infect. 2008;136:436-48.

Agtini MD, Ochiai RL, Soehamo R, Lee HJ, Sundoro J, Hadinegoro SR, et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health. 2006;120:1081-7.

Sharma P, Taneja DK. Typhoid vaccine: a case for inclusion in national program. Indian J Public Health. 2011;55:267-71.

Ochiai RL, Acosta CJ, Agtini M, Bhattacharya KS, Bhutta ZA, Do CG, et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin Infect Dis. 2007;45:s34-8.

Acosta CJ, Hong-Hui Y, Ning W, Qion G, Qun D, Xiaolei M, et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. Vaccine. 2005;23:5618-23.

Kleddy KH, Klugman KP, Hansford CF, Blondeau C, Bouveret le Cam NN. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. Vaccine. 1999;17:110-3.

Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine. 1988;6:307-8.

Pawitro UE, Noorvitry M, Dannowandodo W. Demam tifoid. In: Soegijanto S, editor. Ilmu penyakit anak: diagnosa dan penatalaksanaan, 1st ed. Jakarta: Salemba Medika; 2002. p. 1-43.

Baratawidjaja KG, Rengganis I. Imunologi dasar. 8th ed. Jakarta, FKUI. 2009. p. 557-620.

Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines. 2010;9:485-96.

Froeschle JE, Decker MD. Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine. 2010;28:1451-3.

Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J. 2007;26:1001-5.